GLP-1 Vision-Loss Docket Accelerates as Both MDLs Approach Decisive Science Rulings

The federal MDL consolidating GLP-1 vision-loss claims grew to 146 pending cases on the July 1, 2026 JPML report — up from 86 in May, roughly 70% growth in two months. MDL 3163, created in December 2025 for claims that semaglutide-class drugs cause non-arteritic anterior ischemic optic neuropathy (NAION), held its gating "Science Day" on June 2, when Judge Karen S. Marston heard non-adversarial scientific presentations from both sides on the causation question.

The vision-loss docket is now the fastest-moving front in the broader GLP-1 litigation. The original gastrointestinal-injury MDL 3094 — covering gastroparesis, ileus, and bowel obstruction claims against Ozempic, Wegovy, Mounjaro, and related drugs — reached 3,848 pending cases on the same report, with summary judgment briefing completing August 7 and Rule 702 expert-admissibility hearings set for September 10-18, 2026. Both MDLs sit before Judge Marston in the Eastern District of Pennsylvania.

Two MDLs, One Judge, Different Trajectories

The NAION cases are smaller in number but may carry outsized settlement weight. Vision loss is sudden, painless, and typically permanent — there is no standard treatment — and the failure-to-warn theory is sharpened by a regulatory split: the European Medicines Agency added NAION as a "very rare" side effect to semaglutide labels in June 2025, while the U.S. label still carries no NAION warning.

The Science Driving the Vision-Loss Claims

The foundational study came from Harvard's Mass Eye and Ear. Published in JAMA Ophthalmology in July 2024, the matched cohort study of 16,827 patients found semaglutide users faced a hazard ratio of 4.28 for NAION among diabetic patients and 7.64 among overweight or obese patients, compared with patients on non-GLP-1 medications. Cumulative 36-month NAION incidence hit 8.9% in the diabetic semaglutide cohort versus 1.8% in comparators.

Why September Could Reshape Both Dockets

Rule 702 hearings are the make-or-break event in pharmaceutical MDLs. If Judge Marston admits plaintiffs' general-causation experts in the GI MDL, bellwether trials follow and settlement pressure builds across both dockets. If she excludes them, thousands of GI cases weaken overnight — though the NAION docket, resting on different science and different experts, would proceed on its own track.

Building the NAION Case File

Qualification screens typically require documented GLP-1 use — Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, or Trulicity — before a NAION diagnosis, confirmed by an ophthalmologist or neuro-ophthalmologist.

The exposure trail is the trap in these cases. A client who got semaglutide through a telehealth platform, filled it at a compounding pharmacy, and later saw a hospital ophthalmologist has records in three systems that don't talk to each other — and telehealth prescribers are the providers clients most often forget to name. AI-powered retrieval services like LlamaLab pull pharmacy, prescriber, and specialist records across all of them in 24-48 hours, which matters when both MDLs are adding cases monthly and screening volume keeps climbing — a dynamic we broke down in our GLP-1 litigation surge analysis.

What's Next

The Bottom Line

The GLP-1 litigation is no longer one story. The GI docket is large and approaching its science verdict; the NAION docket is small, fast-growing, and built on injuries juries understand instantly — permanent blindness with no treatment. September's hearings will tell firms which theory carries the litigation.

Either way, the cases that survive will be the ones with complete exposure records and specialist-confirmed diagnoses. With tens of millions of Americans on GLP-1 drugs, screening discipline — not intake volume — is the competitive edge.

Sources: JPML Statistics Report, July 1, 2026, JAMA Ophthalmology — Hathaway et al. 2024, Mass Eye and Ear Press Release, MDL Update — MDL 3163, Lawsuit Status Guide — MDL 3094 Schedule, Miller & Zois — GLP-1 Litigation Updates. Case counts current as of the July 1, 2026 JPML report.

This article provides general information about GLP-1 litigation developments and should not be construed as legal or medical advice. Consult with qualified professionals for advice specific to your situation.